Literature DB >> 9343323

MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities.

R A Soslow1, V Bhargava, R A Warnke.   

Abstract

We propose that 12E7 (CD99) expression, along with TdT, bcl-2, and CD34 reactivity in lymphoblastic lymphoma (LyL)/acute lymphoblastic leukemia (ALL), distinguishes this group of neoplasms from small noncleaved cell lymphomas (SNCLs) in both pediatric and adult patients, thereby narrowing the differential diagnosis of high-grade non-Hodgkin's lymphomas and acute lymphoblastic leukemias in paraffin sections. 12E7 (CD99) is one of a group of available antibodies that recognizes the product of the mic-2 gene, which was originally identified in ALL. Despite this, most clinicopathological research has focused on the reactivity of 12E7 in a subset of the small round cell tumors of childhood. Although TdT is widely used in the subtyping of blastic leukemias, its use in the distinction of high-grade lymphomas in paraffin sections has been limited. We collected 24 cases of LyL/ALL (13 B-cell and 11 T-cell) and 15 cases of SNCL from 1984 through 1993. We confirmed the diagnoses using morphology and analysis of immunologic data. We performed immunohistochemistry with the 12E7 antibody, TdT, bcl-2, and CD34 on formalin-fixed, paraffin-embedded material. The patients' ages ranged from 4 to 81 years; nine of the study patients were children. Sixteen of the 24 LyL/ALLs stained with 12E7. In contrast, none of the 15 cases of SNCL reacted with this antibody (chi-square P < .0001). A larger percentage of T-cell LyL/ALLs reacted with 12E7 than did B-cell LyL/ALLs (82% v 54%). Sixteen of 20 LyL/ALLs reacted with the anti-TdT antibody, as compared with none of 11 SNCLs (chi-square P < .0001). Six LyL/ALLs were CD34 positive (of 23), and none of the SNCLs were CD34 positive (0 of 12) (chi-square P = .0519). Bcl-2-positive cases were found among both LyL/ ALLs and SNCLs, although they were more prevalent among LyL/ ALLs (92% v 25%; chi-square P < .0001). When one considers the differential diagnosis of a high-grade lymphoma/acute lymphoblastic leukemia, positive reactions with 12E7, TdT, bcl-2, and CD34 support the diagnosis of LyL/ALL over SNCL. Moreover, we present data that suggests that evaluating for TdT in formalin-fixed paraffin-embedded tissue is a more sensitive test than using either 12E7, bcl-2 or CD34 alone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343323     DOI: 10.1016/s0046-8177(97)90254-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  TDT (-), KIT (+), CD34 (+), CD99 (+) precursor T lymphoblastic leukemia/lymphoma.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

2.  Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens.

Authors:  B Toth; M Wehrmann; E Kaiserling; H P Horny
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

3.  Case series of precursor B-cell lymphoblastic lymphoma.

Authors:  Jin Yong Kim; Sang Yong Om; Su-Jin Shin; Jeong Eun Kim; Dok Hyun Yoon; Cheolwon Suh
Journal:  Blood Res       Date:  2014-12-23

Review 4.  Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis.

Authors:  Marcus Kremer; Leticia Quintanilla-Martínez; Jörg Nährig; Christoph von Schilling; Falko Fend
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

5.  Terminal deoxynucleotidyl transferase negative T-cell lymphoblastic lymphoma in aleukemic patient.

Authors:  Iva Brčić; Boris Labar; Melita Perić-Balja; Sandra Bašić-Kinda; Marin Nola
Journal:  Int J Hematol       Date:  2008-05-31       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.